Research programme: zidovudine prodrugs

Alternative Names: Zidovudine prodrugs research programme

Latest Information Update: 14 Sep 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Burroughs Wellcome; Medivir AB; Nonindustrial source; Vical
Developer Burroughs Wellcome; Fresh Tracks Therapeutics; Medivir AB; Nonindustrial source
Class Antivirals
Mechanism of Action RNA-directed DNA polymerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

07 Sep 2022 Brickell Biotech Inc is now called Fresh Tracks Therapeutics
31 Aug 2019 Brickell Biotech has merged with Vical to form Brickell Biotech Inc, and subsequently Brickell Biotech changed its name to Brickell Subsidiary
30 Jun 1999 Discontinued-Preclinical for HIV infections treatment in Sweden (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com